1. Home
  2. India
  3. Modi behind campaign against Gadkari, says RSS man

Modi behind campaign against Gadkari, says RSS man

[email protected] (IANS)
November 12, 2012

mg-vaidya

New Delhi, November 12: The needle of suspicion in the campaign against Bharatiya Janata Party (BJP) chief Nitin Gadkari points to Gujarat Chief Minister Narendra Modi, senior Rashtriya Swayamsevak Sangh (RSS) ideologue M.G. Vaidya said Monday.

Vaidya had said in a blog entry Sunday: "The roots of the campaign against Nitin Gadkari have to be in Gujarat because when Ram Jethmalani demanded Gadkari's resignation, he also demanded that Narendra Modi be made the prime ministerial candidate of the party."

On Monday, as the controversy grew, he explained: "And because Jethmalani has combined the two things in one statement, demanding Nitin Gadkari's resignation and making Narendra Modi as PM, I said that the needle of suspicion goes to Gujarat. I only said needle of suspicion goes towards Modi, and that there is a suspicion. And if Jethmalani is entitled to his own point of view, I also am entitled to my own point of view."

"The RSS has nothing to do with it," he told Times Now channel.In an English translation of the Marathi blog, he had also written that "Modi himself seems to have strong prime ministerial ambitions because L.K. Advani and Nitin Gadkari have already said that they are not in the race for the PM. But Narendra Modi has still not said anything on this issue".

"Narendra Modi might have felt that Gadkari as the BJP president will hamper his chances of becoming the prime minster. He is using Jethmalani to fulfil his plans," the senior RSS leader alleged.

He also criticised Jethmalani for his open revolt against Gadkari, saying: "Ram Jethmalani should not have expressed his displeasure against Nitin Gadkari publicly. Any BJP member or MP can feel that Nitin Gadkari should resign, but they should raise this issue on the party platform."

Gadkari has been under attack for alleged financial impropriety in connection with his Purti Group. BJP leader Mahesh Jethmalani, also Ram Jethmalani's son, quit the party national executive last week protesting Gadkari's continuation in office in the wake of allegations against him.


Comments

Add new comment

About text formats
  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 22,2020

Mumbai, May 22: The Reserve Bank of India (RBI) on Friday reduced repo rate by 40 basis points to 4 per cent in an effort to further boost liquidity in the economy which has been reeling under the impact of COVID-19 induced countrywide lockdown.

As a result, the reverse repo rate stands at 3.35 per cent, said RBI Governor Shaktikanta Das. The six-member monetary policy committee (MPC) voted 5:1 in favour of the decision.

Repo rate is the rate at which a country's central bank lends money to commercial banks, and the reverse repo rate is the rate at which it borrows from them. 

Comments

Add new comment

About text formats
  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
April 30,2020

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.

Comments

Add new comment

About text formats
  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 3,2020

New Delhi, Aug 3: India's COVID-19 tally crossed the 18 lakh mark with 52,972 positive cases and 771 deaths reported in the last 24 hours.

The total COVID-19 cases stand at 18,03,696 including 5,79,357 active cases, 11,86,203 cured/discharged/migrated and 38,135 deaths," said the Union Ministry of Health and Family Welfare on Monday.

As per the data provided by the Health Ministry, Maharashtra -- the worst affected state from the infection -- has a total of 1,48,843 active cases and 15,576 deaths. A total of 4,41,228 coronavirus cases have been recorded in the state up to Sunday.

Tamil Nadu has reported a total of 56,998 active cases and 4,132 deaths. While Delhi has recorded 10,356 active cases, 1,23,317 recovered/discharged/migrated cases and 4,004 deaths.

The COVID-19 samples tested across the country has crossed the 2 crore mark till August 2.

The total number of COVID-19 samples tested up to August 2 is 2,02,02,858 including 3,81,027 tests that were conducted yesterday, said Indian Council of Medical Research (ICMR) on Monday. 

Comments

Add new comment

About text formats
  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.